Thanks, byeirvine, That does clarify the separa
Post# of 36536
That does clarify the separation of the $5MM and the $50MM. Yet I still see the $50MM remaining as an option that the Chinese can take or not take by exercising/paying.
I'm curious on your findings after your review. Did you find anything down the path that shows that the Chinese group has exercised this right and would mean that the $50MM would currently be owed to NGIO/GNBT? I have not seen any such disclosure. And it would seem to me that a $50MM licensing fee would be a material event requiring an 8K.
Not saying I couldn't have missed something!
A $50MM addition to receivables would truly be significant... even more significant upon receipt!!!
(Here's my quote for reference:
"Upon payment of the $5,000,000 (Five Million USD) licensing fee, the Joint entity will obtain a right of first refusal for the Ii-Key vaccine technology for oncology, infectious disease and autoimmune diseases for a license fee of $50,000,000 (Fifty Million USD)."